Acute Coronary Syndrome Market Size, Scope And Growth 2025 To 2034

Use Code ONLINE20 to Save 20% On Global Market Reports – Gain Access to Trusted Market Data, Growth Indicators, and Industry Analytics

What Is the Current Size and Annual Growth Rate of the Acute Coronary Syndrome Market?
The acute coronary syndrome market size has grown strongly in recent years. It will grow from $9.86 billion in 2024 to $10.43 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to public health initiatives, adoption of telemedicine and remote monitoring, improved emergency medical services, demand for patient education.

The acute coronary syndrome market size is expected to see strong growth in the next few years. It will grow to " $13.43 billion in 2029 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to demand for personalized medicine, increase in interventional cardiology, increasing awareness, global aging population. Major trends in the forecast period include advancements in diagnostic tools, integration of health information technology, rapid response systems, technological advancements.

Get your free report sample today:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12985&type=smp

Which Core Market Drivers Are Influencing the Development of the Acute Coronary Syndrome Market?
The increasing prevalence of chronic diseases such as coronary artery disease, ischemic heart disease and vascular diseases is expected to propel the growth of the acute coronary syndrome market going forward. Ischemic heart disease is a chronic disease caused by the obstruction or narrowing of the coronary arteries. The treatment of acute coronary syndrome (ACS) is aimed at promptly relieving symptoms, minimizing heart damage and preventing further complications for patients suffering from various acute coronary syndromes, including ischemic heart disease and vascular diseases. For instance, in August 2022, according to a study published in the Journal of the American College of Cardiology, a US-based organization, all four cardiovascular risk factors are anticipated to rise among the general U.S. population between 2025 and 2060, dyslipidemia increased by 27.6%, and hypertension by 25.1%. The researchers discovered that heart failure (33.4%) and ischemic heart disease (30.7%) had the biggest anticipated increases in rates, followed by heart attack (16.9%) and stroke (33.8%). Therefore, the prevalence of chronic diseases such as coronary artery disease, ischemic heart disease and vascular diseases drives the acute coronary syndrome market.

Which Market Segment Offers the Most Significant Growth Opportunities in the Acute Coronary Syndrome Market?
The acute coronary syndromemarket covered in this report is segmented –

1) By Type: Non-St-Elevation Myocardial Infarction; St-Elevation Myocardial Infarction; Unstable Angina
2) By Treatment: Medications; Statins; Beta blockers; ACE inhibitors; Anticoagulants; Other Treatment
3) By Diagnosis: Stress Test; Blood Tests; Imaging; Other Diagnosis
4) By Route Of Administration: Oral; Parenteral
5) By End-User: Hospitals; Specialty clinics; Other End User

Subsegments:
1) By Non-ST-Elevation Myocardial Infarction: Medical Management; Percutaneous Coronary Intervention (PCI); Coronary Artery Bypass Grafting (CABG)
2) By ST-Elevation Myocardial Infarction: Medical Management; Percutaneous Coronary Intervention (PCI); Coronary Artery Bypass Grafting (CABG)
3) By Unstable Angina: Medical Management; Percutaneous Coronary Intervention (PCI); Coronary Artery Bypass Grafting (CABG)

Which Future-Ready Trends Are Expected to Influence the Acute Coronary Syndrome Market?
Major companies operating in the acute coronary syndrome market are developing innovative drugs to treat acute coronary syndrome and sustain their position in the market. The advancements in drug development can increase the efficiency of ACS treatment, reducing the time and resources required for each patient. For instance, in June 2023, AGEPHA Pharma USA LLC, a US-based pharmaceutical company, launched Lodoco, which was approved by the Food and Drug Administration (FDA), a US-based government agency. This is the first anti-inflammatory atheroprotective cardiovascular treatment that reduces the risk of heart stroke, coronary revascularization, myocardial infarction (MI) and cardiovascular death in adult patients with cardiovascular diseases, including acute coronary syndrome.

Who Are the Top Performers and Innovators in the Acute Coronary Syndrome Market?
Major companies operating in the acute coronary syndrome market are Pfizer Inc., Johnson and Johnson Limited, Siemens AG, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories, Medtronic PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Co Ltd., Stryker Corporation, GE Healthcare Inc., Boehringer Ingelheim International GmbH, Boston Scientific Corporation, Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited, Terumo Corp., BioMérieux SA, Beckman Coulter Inc., Quidel Corporation, Bio-Rad Laboratories Inc., Biotronik Inc., Randox Laboratories Limited, Nihon Kohden Corporation, Trinity Biotech plc.

Get the detailed acute coronary syndrome market report today
https://www.thebusinessresearchcompany.com/report/acute-coronary-syndrome-global-market-report

Which Regional Markets Are Likely to See the Most Significant Expansion in the Coming Years?
North America was the largest region in the acute coronary syndrome market in 2024. The regions covered in acute coronary syndrome market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company